Oncosil Medical Ltd

OSL.ASX

Health Care

Medical device

Market Data

Price

$0.490

-0.0%
Market Cap

$15.8M

P/E Ratio

-100000.0x

EPS

$-0.942

Div. Yield

0.00%

52-Week Change

-0.6%

Latest Earnings

Appendix 4D and Half Year Accounts

24 February 2026

Revenue
$0.78
+70.5% YoY
NPAT
-$4.53
+32.5% YoY
EPS
$-0.24

OncoSil Medical reported record dose sales (up 100% vs 1H FY25) and cash receipts of $1.2M (up 184%), with revenue growing 70.5% to $783k. Despite strong commercial momentum and expansion into new European markets, the company posted a net loss of $4.5M, though this was 32.5% lower than the previous year's loss. The company raised $8M in capital to support ongoing commercial expansion. Key points: Record dose sales increased 100% and cash receipts up 184% to $1.2M in 1H FY26; Revenue growth of 70.5% to $783k driven by both direct hospital and distributor sales; Successful expansion into new European markets with first treatments in Germany, UK and Portugal

Recent Announcements

19 Mar 2026 Sph Neutral

Becoming a substantial holder

Regal Partners Funds Management Pty Ltd and its associates (see Annexure 1) became a substantial holder.

24 Feb 2026 Actual Results Positive

Appendix 4D and Half Year Accounts

OncoSil Medical reported record dose sales (up 100% vs 1H FY25) and cash receipts of $1.2M (up 184%), with revenue growing 70.5% to $783k. Despite strong commercial momentum and expansion into new European markets, the company posted a net loss of $4.5M, though this was 32.5% lower than the previous year's loss. The company raised $8M in capital to support ongoing commercial expansion. Key points: Record dose sales increased 100% and cash receipts up 184% to $1.2M in 1H FY26; Revenue growth of 70.5% to $783k driven by both direct hospital and distributor sales; Successful expansion into new European markets with first treatments in Germany, UK and Portugal

13 Feb 2026 Sph Neutral

Ceasing to be a substantial holder

UBS Group AG ceased to be a substantial holder.

11 Feb 2026 Sph Neutral

Becoming a substantial holder

UBS Group AG and its related bodies corporate became a substantial holder in OncoSil Medical Ltd on 9 February 2026, acquiring 1,429,821 ordinary shares representing 6.05% voting power through a series of purchases from October 2025 to February 2026.

Get real-time alerts for OSL

Receive AI-powered earnings summaries and instant notifications when Oncosil Medical Ltd releases results.

Register Free